RMD vs. BSX, MDT, BDX, EW, DXCM, IDXX, STE, BAX, HOLX, and PODD
Should you be buying ResMed stock or one of its competitors? The main competitors of ResMed include Boston Scientific (BSX), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), STERIS (STE), Baxter International (BAX), Hologic (HOLX), and Insulet (PODD). These companies are all part of the "health care equipment" industry.
Boston Scientific (NYSE:BSX) and ResMed (NYSE:RMD) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, community ranking, risk, valuation, profitability, institutional ownership and earnings.
In the previous week, Boston Scientific had 28 more articles in the media than ResMed. MarketBeat recorded 40 mentions for Boston Scientific and 12 mentions for ResMed. Boston Scientific's average media sentiment score of 0.96 beat ResMed's score of 0.30 indicating that ResMed is being referred to more favorably in the news media.
Boston Scientific currently has a consensus target price of $76.70, suggesting a potential upside of 1.49%. ResMed has a consensus target price of $202.80, suggesting a potential downside of 1.71%. Given ResMed's stronger consensus rating and higher possible upside, research analysts plainly believe Boston Scientific is more favorable than ResMed.
Boston Scientific has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, ResMed has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.
ResMed has a net margin of 20.91% compared to ResMed's net margin of 12.06%. Boston Scientific's return on equity of 24.43% beat ResMed's return on equity.
89.1% of Boston Scientific shares are owned by institutional investors. Comparatively, 55.0% of ResMed shares are owned by institutional investors. 0.5% of Boston Scientific shares are owned by insiders. Comparatively, 1.2% of ResMed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Boston Scientific has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
Boston Scientific received 586 more outperform votes than ResMed when rated by MarketBeat users. Likewise, 69.37% of users gave Boston Scientific an outperform vote while only 52.93% of users gave ResMed an outperform vote.
Summary
Boston Scientific beats ResMed on 13 of the 19 factors compared between the two stocks.
Get ResMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
